Multiparametric In-vitro Cardiotoxicity Testing Market

Multiparametric In-vitro Cardiotoxicity Testing Market (Type of Assay: Calcium Transient Assay, Cardiac Marker Detection, hERG Assay, Multi-ion Channel Assay, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Multiparametric In-vitro Cardiotoxicity Testing Market Outlook

  • The global industry was valued at US$ 44.5 Mn in 2021
  • It is projected to advance at a CAGR of 13.9% from 2022 to 2031 and reach more than US$ 166.5 Mn by the end of 2031

Analysts’ Viewpoint on Market Scenario

The global multiparametric in-vitro cardiotoxicity testing market size is expected to grow at a rapid pace from 2022 to 2031, led by the rise in demand for effective and affordable techniques to assess the safety of drugs. Multiparametric in-vitro cardiotoxicity testing is used to evaluate the possible toxic effects of chemicals and other compounds on the heart.

In-vitro testing can be a suitable alternative for conventional approaches employed to determine the safety of various pharmaceuticals. Implementation of stringent regulatory policies to test drug safety and surge in need for safe pharmaceutical drugs are anticipated to propel multiparametric in-vitro cardiotoxicity testing industry statistics during the forecast period.

Multiparametric In Vitro Cardiotoxicity Testing Market

Market Introduction

Multiparametric in-vitro cardiotoxicity test is performed using cells or tissue culture systems in a laboratory setting, rather than in living organisms. It is used to assess the safety of a wide range of substances, including pharmaceuticals, industrial chemicals, and consumer products.

Multiparametric in-vitro cardiotoxicity tests can be conducted on tissue samples or organoids, primary cells, established cell lines, or cell cultures (three-dimensional tissue cultures that mimic the structure and function of organs). These tests are cost-effective and efficient alternatives to animal testing.

Request a sample to get extensive insights into the Multiparametric In-vitro Cardiotoxicity Testing Market

Rise in Investment in R&D of New Drugs Fueling Multiparametric In-vitro Cardiotoxicity Testing Market Value

Various pharmaceutical companies are investing significantly in R&D of new therapies due to the rise in prevalence of chronic diseases. They are seeking more reliable and accurate methods to determine the efficacy and safety of these therapies.

In-vitro cardiotoxicity testing uses cell- or tissue-based models to study the potential effects of a drug on the heart. It plays an important role in assessing the risks of new medications, particularly those designed for the treatment of cardiovascular disorders. Thus, high incidence of cardiovascular diseases is estimated to contribute to multiparametric in-vitro cardiotoxicity testing market growth in the next few years.

Key pharmaceutical companies are investing in multiparametric in-vitro cardiotoxicity testing to determine the potential risks of new treatments. This gives in-depth insights into the development and commercialization of potential drugs. Investment in drug discovery has witnessed rapid growth in the recent past due to the rise in cases of chronic and infectious diseases. This, in turn, is likely to drive the multiparametric in-vitro cardiotoxicity testing market revenue in the near future.

Increase in Outsourcing of Toxicological Studies

Various stakeholders in the life sciences sector are opting for strategic alliances with Contract Research Organizations (CROs). Biopharmaceutical companies are under intense pressure to reduce the cost of drug discovery and development. Therefore, these companies prefer to outsource R&D activities to CROs. They also outsource non-core services, such as toxicity research, thereby augmenting multiparametric in-vitro cardiotoxicity testing market development.

Toxicological studies have become more sophisticated and require extensive experience in toxicological testing. Outsourcing toxicological studies can help address the limitations of in-house toxicological research, such as a lack of skilled labor, dearth of sophisticated tools and technologies, and lack of expertise in regulatory standards. This is likely to boost market expansion in the next few years.

Request a custom report on Multiparametric In-vitro Cardiotoxicity Testing Market

Extensive Usage of Calcium Transient Assays

According to the latest multiparametric in-vitro cardiotoxicity testing market analysis, the calcium transient assay segment accounted for the largest share in 2021. Calcium transient tests are used to measure calcium concentration. The ability of muscle cells to contract, particularly cardiomyocytes, plays an important role in determining compound-induced cardiotoxicity.

Calcium transient assays provide valuable information about the effects of a substance on the function of heart cells. Calcium ions play a critical role in the contraction of heart muscle cells. Changes in concentration of calcium ions inside the cells can indicate potential disruptions in normal heart function.

Contract Research Organizations Gaining Traction

The Contract Research Organizations (CROs) end-user segment dominated the market in 2021. Outsourcing in-vitro cardiotoxicity testing to a CRO can be more cost-effective than conducting the testing in-house.

CROs possess specialized equipment and trained personnel. They can often complete the testing more efficiently and at a lower cost than a company can with less experience in the field. CROs often have the capacity to handle large volumes of testing and can provide rapid turnaround times for results.

Regional Outlook

North America is projected to hold the largest share of the industry during the forecast period. Rise in need for safe and high-quality cosmetic products is likely to boost the multiparametric in-vitro cardiotoxicity testing market share of the region in the next few years. Several stakeholders in healthcare and pharmaceutical sectors in North America are collaborating with CROs for preclinical product testing.

The market in Europe is expected to grow at a significant pace during the forecast period. Increase in prevalence of cardiovascular diseases and surge in investment in drug discovery and development are driving market progress in the region.

The market in Asia Pacific is driven by the rise in cost of preclinical and clinical testing in the region. Pharmaceutical companies in developing countries, such as China, India, and Japan, are partnering with CROs to obtain rapid outcomes in drug testing at low costs.

Increase in investment in healthcare and pharmaceutical sectors and rise in consumer awareness about the safety of drugs are likely to fuel market statistics in Rest of the World (Latin America and Middle East & Africa) during the forecast period.

Analysis of Key Players in Multiparametric In-vitro Cardiotoxicity Testing Market

The market report profiles various vendors based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments. The global industry is fragmented, with the presence of a large number of leading service providers.

Creative Bioarray, Agilent Technologies, Inc., Hemogenix Inc., Merck KGaA, Molecular Devices, LLC., Evotec, Miltenyi Biotec, FUJIFILM Cellular Dynamics, Enzo Life Sciences, Inc., Axol Bioscience Ltd., Stemina Biomarker Discovery, Inc., Eurofins Discovery, and emka TECHNOLOGIES are prominent companies operating in this market.

Key Developments in Multiparametric In-vitro Cardiotoxicity Testing Industry

  • In September 2022, HeartBeat.bio and Molecular Devices LLC (Danaher) announced their partnership to scale and automate the usage of cardiac organoids for high-throughput drug discovery testing
  • In June 2022, Axol Bioscience Ltd. launched Comprehensive In-vitro Pro-arrhythmia Assay (CiPA)-validated human stem cell-derived ventricular cardiomyocytes to measure cardiotoxicity during drug discovery and screening

Global Multiparametric In-vitro Cardiotoxicity Testing Market Snapshot

Attribute

Detail

Size in 2021

US$ 44.5 Mn

Forecast Value in 2031

More than US$ 166.5 Mn

CAGR - 2022–2031

13.9%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Type of Assay
    • Calcium Transient Assay
    • Cardiac Marker Detection
    • hERG Assay
    • Multi-ion Channel Assay
    • Others
  • End-user
    • Contract Research Organizations (CROs)
    • Pharmaceutical and Biotech Companies
    • Others

.Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Creative Bioarray
  • Agilent Technologies, Inc.
  • Hemogenix Inc.
  • Merck KGaA
  • Molecular Devices, LLC.
  • Miltenyi Biotec
  • FUJIFILM Cellular Dynamics
  • Enzo Life Sciences, Inc.
  • Axol Bioscience Ltd.
  • emka TECHNOLOGIES
  • Eurofins Discovery
  • Stemina Biomarker Discovery, Inc.
  • Evotec

Customization Scope

Available upon Request

Pricing

Available upon Request

Frequently Asked Questions

How big was the global multiparametric in-vitro cardiotoxicity testing market in 2021?

It was valued at US$ 44.5 Mn in 2021.

How big will be the industry size in 2031?

It is projected to reach more than US$ 166.5 Mn by 2031.

What will be the CAGR during the forecast period?

It is anticipated to be 13.9% from 2022 to 2031.

What was the share of the leading segment?

The Contract Research Organizations (CROs) segment held more than 45.0% share in 2021.

Which region will account for major share during the forecast period?

North America is expected to account for the largest share from 2022 to 2031.

Who are the prominent players in the business?

Creative Bioarray, Agilent Technologies, Inc., Hemogenix Inc., Merck KGaA, Molecular Devices, LLC., Evotec, Miltenyi Biotec, FUJIFILM Cellular Dynamics, Enzo Life Sciences, Inc., Axol Bioscience Ltd., Stemina Biomarker Discovery, Inc., Eurofins Discovery, and emka TECHNOLOGIES.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Multiparametric In-vitro Cardiotoxicity Testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, 2017 - 2031

            4.4.1. Market Revenue Projection (US$ Mn)

    5. Key Insights

        5.1. Key Industry Developments

        5.2. Key Product/Brand Analysis

        5.3. Emerging Technologies and Platforms for Cardiotoxicity Testing

        5.4. Overview of In-vitro Cardiac Electrophysiology Platforms for Toxicology Assessment

        5.5. Overview of Multiparametric In-vitro Toxicology Assessment

        5.6. COVID-19 Impact Analysis

    6. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By Type of Assay

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast By Type of Assay, 2017 - 2031

            6.3.1. Calcium Transient Assay

            6.3.2. Cardiac Marker Detection

            6.3.3. hERG Assay

            6.3.4. Multi-ion Channel Assay

            6.3.5. Others

        6.4. Market Attractiveness By Type of Assay

    7. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By End-user

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast By End-user, 2017 - 2031

            7.3.1. Contract Research Organizations (CROs)

            7.3.2. Pharmaceutical and Biotech Companies

            7.3.3. Others

        7.4. Market Attractiveness By End-user

    8. Global Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast, By Region

        8.1. Key Findings

        8.2. Market Value Forecast By Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Rest of the World

        8.3. Market Attractiveness By Country/Region

    9. North America Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast By Type of Assay, 2017 - 2031

            9.2.1. Calcium Transient Assay

            9.2.2. Cardiac Marker Detection

            9.2.3. hERG Assay

            9.2.4. Multi-ion Channel Assay

            9.2.5. Others

        9.3. Market Value Forecast By End-user, 2017 - 2031

            9.3.1. Contract Research Organizations (CROs)

            9.3.2. Pharmaceutical and Biotech Companies

            9.3.3. Others

        9.4. Market Value Forecast By Country, 2017 - 2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Type of Assay

            9.5.2. By End-user

            9.5.3. By Country

    10. Europe Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast By Type of Assay, 2017 - 2031

            10.2.1. Calcium Transient Assay

            10.2.2. Cardiac Marker Detection

            10.2.3. hERG Assay

            10.2.4. Multi-ion Channel Assay

            10.2.5. Others

        10.3. Market Value Forecast By End-user, 2017 - 2031

            10.3.1. Contract Research Organizations (CROs)

            10.3.2. Pharmaceutical and Biotech Companies

            10.3.3. Others

        10.4. Market Value Forecast By Country/Sub-region, 2017 - 2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Type of Assay

            10.5.2. By End-user

            10.5.3. By Country/Sub-region

    11. Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Type of Assay, 2017 - 2031

            11.2.1. Calcium Transient Assay

            11.2.2. Cardiac Marker Detection

            11.2.3. hERG Assay

            11.2.4. Multi-ion Channel Assay

            11.2.5. Others

        11.3. Market Value Forecast By End-user, 2017 - 2031

            11.3.1. Contract Research Organizations (CROs)

            11.3.2. Pharmaceutical and Biotech Companies

            11.3.3. Others

        11.4. Market Value Forecast By Country/Sub-region, 2017 - 2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Type of Assay

            11.5.2. By End-user

            11.5.3. By Country/Sub-region

    12. Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Type of Assay, 2017 - 2031

            12.2.1. Calcium Transient Assay

            12.2.2. Cardiac Marker Detection

            12.2.3. hERG Assay

            12.2.4. Multi-ion Channel Assay

            12.2.5. Others

        12.3. Market Value Forecast By End-user, 2017 - 2031

            12.3.1. Contract Research Organizations (CROs)

            12.3.2. Pharmaceutical and Biotech Companies

            12.3.3. Others

        12.4. Market Attractiveness Analysis

            12.4.1. By Type of Assay

            12.4.2. By End-user

    13. Competition Landscape

        13.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        13.2. Market Share Analysis By Company (2021)

        13.3. Company Profiles

            13.3.1. Creative Bioarray

                13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.1.2. Product Portfolio

                13.3.1.3. SWOT Analysis

                13.3.1.4. Strategic Overview

            13.3.2. Agilent Technologies, Inc.

                13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.2.2. Product Portfolio

                13.3.2.3. SWOT Analysis

                13.3.2.4. Strategic Overview

            13.3.3. Hemogenix Inc.

                13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.3.2. Product Portfolio

                13.3.3.3. SWOT Analysis

                13.3.3.4. Strategic Overview

            13.3.4. Merck KGaA

                13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.4.2. Product Portfolio

                13.3.4.3. SWOT Analysis

                13.3.4.4. Strategic Overview

            13.3.5. Molecular Devices, LLC

                13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.5.2. Product Portfolio

                13.3.5.3. SWOT Analysis

                13.3.5.4. Strategic Overview

            13.3.6. Evotec

                13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.6.2. Product Portfolio

                13.3.6.3. SWOT Analysis

                13.3.6.4. Strategic Overview

            13.3.7. Miltenyi Biotec

                13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.7.2. Product Portfolio

                13.3.7.3. SWOT Analysis

                13.3.7.4. Strategic Overview

            13.3.8. FUJIFILM Cellular Dynamics

                13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.8.2. Product Portfolio

                13.3.8.3. SWOT Analysis

                13.3.8.4. Strategic Overview

            13.3.9. Enzo Life Sciences, Inc.

                13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.9.2. Product Portfolio

                13.3.9.3. SWOT Analysis

                13.3.9.4. Strategic Overview

            13.3.10. Axol Bioscience Ltd.

                13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.10.2. Product Portfolio

                13.3.10.3. SWOT Analysis

                13.3.10.4. Strategic Overview

            13.3.11. Stemina Biomarker Discovery, Inc.

                13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.11.2. Product Portfolio

                13.3.11.3. SWOT Analysis

                13.3.11.4. Strategic Overview

            13.3.12. emka TECHNOLOGIES

                13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.12.2. Product Portfolio

                13.3.12.3. SWOT Analysis

                13.3.12.4. Strategic Overview

            13.3.13. Eurofins Discovery

                13.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.13.2. Product Portfolio

                13.3.13.3. SWOT Analysis

                13.3.13.4. Strategic Overview

    List of Tables

    Table 01: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 02: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 03: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 05: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 06: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 07: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 08: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 09: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 10: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 11: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 12: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by Type of Assay, 2017‒2031

    Table 14: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Multiparametric In-vitro Cardiotoxicity Testing Market Value Share, by Type of Assay, 2021

    Figure 03: Multiparametric In-vitro Cardiotoxicity Testing Market Value Share, by End-user, 2021

    Figure 04: Multiparametric In-vitro Cardiotoxicity Testing Market Value Share, by Region, 2021

    Figure 05: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Type of Assay, 2021 and 2031

    Figure 06: Global Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Type of Assay, 2022–2031

    Figure 07: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn), by Calcium Transient Assay, 2017‒2031

    Figure 08: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn), by Cardiac Marker Detection, 2017‒2031

    Figure 09: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn), by hERG Assay, 2017‒2031

    Figure 10: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn), by Multi-ion Channel Assay, 2017‒2031

    Figure 11: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn), by others, 2017‒2031

    Figure 12: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 13: Global Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 14: Global Multiparametric In-vitro Cardiotoxicity Testing Market Revenue (US$ Mn), by Contract Research Organizations (CROs), 2017–2031

    Figure 15: Global Multiparametric In-vitro Cardiotoxicity Testing Market Revenue (US$ Mn), by Pharmaceutical and Biotech Companies, 2017–2031

    Figure 16: Global Multiparametric In-vitro Cardiotoxicity Testing Market Revenue (US$ Mn), by others, 2017–2031

    Figure 17: Global Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Region, 2021 and 2031

    Figure 18: Global Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Region, 2022–2031

    Figure 19: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 20: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Country, 2021 and 2031

    Figure 21: North America Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Country, 2022–2031

    Figure 22: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Type of Assay, 2021 and 2031

    Figure 23: North America Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Type of Assay 2022–2031

    Figure 24: North America Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 25: North America Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 26: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 27: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 28: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 29: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Type of Assay, 2021 and 2031

    Figure 30: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Type of Assay 2022–2031

    Figure 31: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 32: Europe Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 33: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 34: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 35: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 36: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Type of Assay, 2021 and 2031

    Figure 37: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Type of Assay 2022–2031

    Figure 38: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 39: Asia Pacific Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 40: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Value (US$ Mn) Forecast, 2017–2031

    Figure 41: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by Type of Assay, 2021 and 2031

    Figure 42: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by Type of Assay 2022–2031

    Figure 43: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 44: Rest of the World Multiparametric In-vitro Cardiotoxicity Testing Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 45: Company Share Analysis, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved